123 related articles for article (PubMed ID: 30129165)
1. Exploring the effect of E76K mutation on SHP2 cause gain-of-function activity by a molecular dynamics study.
Li WY; Wei HY; Sun YZ; Zhou H; Ma Y; Wang RL
J Cell Biochem; 2018 Dec; 119(12):9941-9956. PubMed ID: 30129165
[TBL] [Abstract][Full Text] [Related]
2. Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study.
Li HL; Ma Y; Zheng CJ; Jin WY; Liu WS; Wang RL
J Biomol Struct Dyn; 2018 Nov; 36(14):3856-3868. PubMed ID: 29125030
[TBL] [Abstract][Full Text] [Related]
3. Gain-of-Function SHP2 E76Q Mutant Rescuing Autoinhibition Mechanism Associated with Juvenile Myelomonocytic Leukemia.
Rehman AU; Rafiq H; Rahman MU; Li J; Liu H; Luo S; Arshad T; Wadood A; Chen HF
J Chem Inf Model; 2019 Jul; 59(7):3229-3239. PubMed ID: 31244092
[TBL] [Abstract][Full Text] [Related]
4. Exploring the reason for increased activity of SHP2 caused by D61Y mutation through molecular dynamics.
Wang RR; Ma Y; Du S; Li WY; Sun YZ; Zhou H; Wang RL
Comput Biol Chem; 2019 Feb; 78():133-143. PubMed ID: 30508783
[TBL] [Abstract][Full Text] [Related]
5. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
[TBL] [Abstract][Full Text] [Related]
6. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK
J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
Elife; 2022 May; 11():. PubMed ID: 35535491
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia.
He C; Peng Z; Zhang D; Guo Y; Liang T; Zhao Y; Yu L; Zhang Q; Chang Z; Xiao Y; Li N; Xue H; Wu S; Zhao ZJ; Zhang C; Chen Y
Biochem Pharmacol; 2023 Jul; 213():115588. PubMed ID: 37187274
[TBL] [Abstract][Full Text] [Related]
9. The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/β-catenin signaling pathway.
Zhang Q; Li Y; Zhao R; Wang X; Fan C; Xu Y; Liu Y; Li J; Wang S
Mol Carcinog; 2018 May; 57(5):619-628. PubMed ID: 29323748
[TBL] [Abstract][Full Text] [Related]
10. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
[TBL] [Abstract][Full Text] [Related]
11. Role of lncRNA Morrbid in PTPN11(Shp2)E76K-driven juvenile myelomonocytic leukemia.
Cai Z; Zhang C; Kotzin JJ; Williams A; Henao-Mejia J; Kapur R
Blood Adv; 2020 Jul; 4(14):3246-3251. PubMed ID: 32697817
[TBL] [Abstract][Full Text] [Related]
12. Investigating the reason for loss-of-function of Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) caused by Y279C mutation through molecular dynamics simulation.
Liu WS; Wang RR; Li WY; Rong M; Liu CL; Ma Y; Wang RL
J Biomol Struct Dyn; 2020 Jun; 38(9):2509-2520. PubMed ID: 31258001
[TBL] [Abstract][Full Text] [Related]
13. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
[TBL] [Abstract][Full Text] [Related]
14. Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
Tarnawsky SP; Yoshimoto M; Deng L; Chan RJ; Yoder MC
Dev Dyn; 2017 Dec; 246(12):1001-1014. PubMed ID: 28975680
[TBL] [Abstract][Full Text] [Related]
15. Exploring the effect of N308D mutation on protein tyrosine phosphatase-2 cause gain-of-function activity by a molecular dynamics study.
Sun YZ; Chen XB; Wang RR; Li WY; Ma Y
J Cell Biochem; 2019 Apr; 120(4):5949-5961. PubMed ID: 30304563
[TBL] [Abstract][Full Text] [Related]
16. SHP2E76K mutant promotes lung tumorigenesis in transgenic mice.
Schneeberger VE; Luetteke N; Ren Y; Berns H; Chen L; Foroutan P; Martinez GV; Haura EB; Chen J; Coppola D; Wu J
Carcinogenesis; 2014 Aug; 35(8):1717-25. PubMed ID: 24480804
[TBL] [Abstract][Full Text] [Related]
17. Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
Goodwin CB; Yang Z; Yin F; Yu M; Chan RJ
Haematologica; 2012 Jul; 97(7):1042-7. PubMed ID: 22315502
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.
Liu W; Yu WM; Zhang J; Chan RJ; Loh ML; Zhang Z; Bunting KD; Qu CK
Leukemia; 2017 Jun; 31(6):1415-1422. PubMed ID: 27840422
[TBL] [Abstract][Full Text] [Related]
19. Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2
Du S; Lu XH; Li WY; Li LP; Ma YC; Zhou L; Wu JW; Ma Y; Wang RL
Mol Divers; 2021 Aug; 25(3):1873-1887. PubMed ID: 33392964
[TBL] [Abstract][Full Text] [Related]
20. Induction of a tumor-associated activating mutation in protein tyrosine phosphatase Ptpn11 (Shp2) enhances mitochondrial metabolism, leading to oxidative stress and senescence.
Zheng H; Li S; Hsu P; Qu CK
J Biol Chem; 2013 Sep; 288(36):25727-25738. PubMed ID: 23884424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
